A detailed history of Bank Of America Corp transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 299,531 shares of RAPT stock, worth $323,493. This represents 0.0% of its overall portfolio holdings.

Number of Shares
299,531
Previous 90,656 230.4%
Holding current value
$323,493
Previous $276,000 118.12%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.76 - $3.75 $367,620 - $783,281
208,875 Added 230.4%
299,531 $602,000
Q2 2024

Aug 14, 2024

SELL
$2.89 - $9.38 $53,751 - $174,458
-18,599 Reduced 17.02%
90,656 $276,000
Q1 2024

May 15, 2024

BUY
$6.87 - $26.45 $108,862 - $419,126
15,846 Added 16.96%
109,255 $981,000
Q4 2023

Feb 14, 2024

BUY
$11.28 - $25.46 $224,517 - $506,755
19,904 Added 27.08%
93,409 $2.32 Million
Q2 2023

Aug 14, 2023

SELL
$16.06 - $21.61 $1.06 Million - $1.42 Million
-65,731 Reduced 47.21%
73,505 $1.37 Million
Q1 2023

May 12, 2023

SELL
$17.19 - $30.8 $67,917 - $121,690
-3,951 Reduced 2.76%
139,236 $2.55 Million
Q4 2022

Feb 10, 2023

BUY
$16.28 - $24.6 $1.53 Million - $2.31 Million
93,849 Added 190.22%
143,187 $2.84 Million
Q3 2022

Nov 14, 2022

BUY
$17.96 - $30.46 $724,721 - $1.23 Million
40,352 Added 449.05%
49,338 $1.19 Million
Q2 2022

Aug 12, 2022

SELL
$10.26 - $23.59 $278,425 - $640,161
-27,137 Reduced 75.12%
8,986 $163,000
Q1 2022

May 16, 2022

SELL
$17.02 - $40.22 $784,792 - $1.85 Million
-46,110 Reduced 56.07%
36,123 $794,000
Q4 2021

Feb 08, 2022

BUY
$29.5 - $39.5 $2.16 Million - $2.89 Million
73,102 Added 800.59%
82,233 $3.02 Million
Q3 2021

Nov 15, 2021

BUY
$29.86 - $39.47 $36,906 - $48,784
1,236 Added 15.66%
9,131 $283,000
Q2 2021

Sep 13, 2021

BUY
$17.99 - $40.02 $142,031 - $315,957
7,895 New
7,895 $250,000

Others Institutions Holding RAPT

About RAPT Therapeutics, Inc.


  • Ticker RAPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,656,600
  • Market Cap $32M
  • Description
  • RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...
More about RAPT
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.